SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Protagonist Therapeutics, Inc. - PTGX - Yahoo Finance
New York, New York--(Newsfile Corp. - September 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ: PTGX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether Protagonist and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On September 17, 2021, Protagonist issued a press release "announc[ing] the receipt of a verbal communication from the U.S. Food and Drug Administration (FDA) that Protagonist's clinical studies for rusfertide, an investigational product candidate currently in development, have been placed on a clinical hold." The press release stated that "[t]he clinical hold follows Protagonist's notification to the FDA of a recent non-clinical finding in a 26-week rasH2 transgenic mouse model study. The rasH2 model is designed to detect signals related to tumorigenicity, and benign and malignant subcutaneous skin tumors were observed in this study."
On this news, Protagonist's stock price fell $28.60 per share, or 62%, to close at $17.53 per share on September 17, 2021.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
source: https://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-185800186.html
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.